We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 267

Pharmacovigilance in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to Pharmacovigilance in China


Life Sciences: Compliance and enforcement in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to compliance and dishonest practices in China


Life Sciences: product regulation and liability in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to product regulation and liability laws in China


Clinical trials in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to clinical trials in China


Antitrust, Competition and Economic Regulation Quarterly Newsletter - Spring 2018
  • Hogan Lovells
  • USA, United Kingdom, OECD, China, Germany
  • June 27 2018

On 17 March 2018, the Chinese legislature decided on a major restructuring of governmental agencies with a profound impact on antitrust enforcement in


Overview of regulatory reform in China
  • Liu, Shen & Associates
  • China
  • May 25 2018

With the development of the economy, China has become the second largest pharmaceuticals market in the world. However, several serious problems are


Fast drugs, new drugs: new opportunities in the healthcare industry in Australia and China
  • King & Wood Mallesons
  • Australia, China
  • April 27 2018

Chinese and Australian businesses looking for overseas opportunities to expand in the healthcare industry should be aware of important regulatory


Pre-revenue Biotech Companies Can Apply For Listing In Hong Kong With Effect From 30 April 2018
  • Baker McKenzie
  • Hong Kong
  • April 26 2018

On 24 April 2018, The Stock Exchange of Hong Kong Limited (HKEx) published its Consultation Conclusions to HKEx's proposals to expand Hong Kong's


China FDA Issues Guidance on 3D Printed Medical Devices
  • Knobbe Martens
  • China
  • April 23 2018

More than two and a half years after the China Food and Drug Administration (CFDA) formally approved its first three-dimensional (3D) printed medical


China’s New State Market Regulatory Administration: What to Know and What to Expect
  • Ropes & Gray LLP
  • China
  • April 3 2018

On March 17, China’s highest legislative body, the National People’s Congress, approved a sweeping government restructuring plan. This is generally